Summary
The steady-state plasma concentrations of antipsychotic drugs show large interpatient variations but remain relatively stable from day to day in each individual patient. Monitoring of antipsychotic drug concentrations in plasma might be of value provided the patients are treated with only 1 antipsychotic drug. Some studies have reported a relationship between therapeutic response and serum antipsychotic drug ‘concentrations’ as measured using the radioreceptor assay (RRA) method, which measures dopamine receptor-blocking activity in plasma. Most studies, however, have failed to demonstrate such a relationship, and the RRA does not seem to provide the generally useful tool for plasma concentration monitoring of antipsychotic drugs that was hoped for initially. A lack of correlation between dopamine receptor-blocking activity in plasma and therapeutic response may be due to differences in the blood-brain distribution of both antipsychotic drugs and their active metabolites.
Chemical assay methods (e.g. GLC and HPLC) have been used in studies which examined the relationships between therapeutic response and antipsychotic drug concentrations in red blood cells and in plasma. It seems that for these drugs, measuring red blood cell concentrations does not offer any significant advantage over measuring plasma concentrations. Reasonably controlled studies of plasma concentration-response relationships using randomly allocated, fixed dosages of chlorpromazine, fluphenazine, haloperidol, perphenazine, sulpiride, thioridazine and thiothixene have been published but often involve relatively few patients. A correlation between therapeutic response and plasma concentrations of thioridazine and its metabolites has not been demonstrated, and plasma level monitoring of thioridazine and its metabolites therefore appears to have no clinical value. Clinical behavioural deterioration concomitant with high plasma concentrations of chlorpromazine and haloperidol have been reported. A dosage reduction might be considered after 2 to 4 weeks’ treatment in non-responders who have plasma chlorpromazine concentrations above 100 to 150 µg/L or plasma haloperidol concentrations above 20 to 30 µg/L. Non-responders and good responders to chlorpromazine treatment, however, have plasma drug concentrations in the same range, and a therapeutic range of plasma chlorpromazine levels has not been defined. Therapeutic plasma haloperidol concentrations (i.e. ‘window’) in the range of 5 to 20 µg/L have been reported by some investigators, but others have found no such relationship. A generally valid therapeutic plasma concentration range for haloperidol has not yet been defined.
Sulpiride appears to have a therapeutic ‘window’ with an upper limit around 1.5 µmol/L. The interindividual variations in plasma sulpiride concentrations appear to be relatively small compared with other antipsychotic drugs and hence may limit the clinical requirements, if any, of plasma level monitoring.
Measuring steady-state plasma drug concentrations may help to obtain an optimal therapeutic response with fluphenazine, perphenazine and thiothixene. Perphenazine appears to have a therapeutic window of 1.2 to 2.4 µg/L; levels greater than 2.4 µg/L may be associated with extrapyramidal side effects. The reported therapeutic ranges for fluphenazine and thiothixene are 0.2 to 2.0 µg/L and 2 to 15 µg/L, respectively. Dosages of fluphenazine and thiothixene may be adjusted from plasma level measurements after 2 weeks of treatment.
Unfortunately, there is no evidence that plasma concentration monitoring of antipsychotic drugs may significantly reduce the incidence of tardive dyskinesia.
Similar content being viewed by others
References
Alfredsson G, Lindberg M, Sedvall G. The presence of 7-hydroxychlorpromazine in CSF of chlorpromazine-treated patients. Psychopharmacology 77: 376–378, 1982
Alfredsson G, Bjerkenstedt L, Edman G, Härnryd C, Oxenstierna G, et al. Relationship between drug concentrations in serum and CSF, clinical effects and monoaminergic variables in schizophrenic patients treated with sulpiride or chlorpromazine. Acta Psychiatrica Scandinavica 69(Suppl. 311): 49–74, 1984a
Alfredsson G, Härnryd C, Wiesel F-A. Effects of sulpiride and chlorpromazine on depressive symptoms in schizophrenic patients — relationship to drug concentrations. Psychopharmacology 84: 237–241, 1984b
Alfredsson G, Härnryd C, Wiesel F-A. Effects of sulpiride and chlorpromazine on autistic and positive psychotic symptoms in schizophrenic patients — relationship to drug concentrations. Psychopharmacology 85: 8–13, 1985
Aravagiri M, Hawes EM, Midha KK. Radioimmunoassay for the sulfoxide metabolite of trifluoperazine and its application to a kinetic study in humans. Journal of Pharmaceutical Sciences 73: 1383–1387, 1984
Axelsson R. On the serum concentrations and antipsychotic effects of thioridazine, thioridazine side-chain sulfoxide and thioridazine side-chain sulfone, in chronic psychiatric patients. Current Therapeutic Research 21: 587–605, 1977
Axelsson R, Mårtensson E. The concentration pattern of non-conjugated thioridazine metabolites in serum by thioridazine treatment and its relationship to physiological and clinical variables. Current Therapeutic Research 21: 561–586, 1977
Axelsson R, Mårtensson E. Side effects of thioridazine and their relationship with the serum concentrations of the drug and its main metabolites. Current Therapeutic Research 28: 463–489, 1980
Axelsson R, Mårtensson E. Clinical effects related to the serum concentrations of thioridazine and its metabolites. In Gram et al. (Eds) Clinical pharmacology in psychiatry — bridging the experimental-therapeutic gap, pp. 165–174, Macmillan, London, 1983
Balant-Gorgia AE, Eisele R, Balant L, Garrone G. Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia. European Archives of Psychiatry and Neurological Sciences 234: 1–4, 1984
Balant-Gorgia AE, Eisele R, Garrone G. Approche quantitative du traitement aux neuroleptiques incisifs par le monitoring thérapeutique (Quantitative approach to neuroleptic treatment by therapeutic drug monitoring). Schweizerische Medizinische Wochenschrift 115: 14–18, 1985
Bigelow LB, Kirch DG, Braun T, Korpi ER, Wagner RL, et al. Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: a fixed-dose study. Psychopharmacology Bulletin 21: 66–68, 1985
Bjørndal N, Bjerre M, Gerlach J, Kristjansen P, Magelund G, et al. High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side-effects, serum haloperidol, and serum prolaltin. Psychopharmacology 67: 17–23, 1980
Bleeker JAC, Dingemans PM, Frohn-de Winther ML, Van de Slooten EPJ. Plasma levels and effect of low-dose haloperidol in acute psychosis. Psychopharmacology Bulletin 20: 317–319, 1984
Bolvig Hansen L. The clinical significance of measuring perphenazine in plasma during oral antipsychotic treatment. In Usdin et al. (Eds) Clinical pharmacology in psychiatry — neuroleptic and antidepressant research, pp. 211–216, Macmillan, London, 1981
Bolvig Hansen L, Elley J, Christensen TR, Larsen N-E, Naestoft J, et al. Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs. British Journal of Clinical Pharmacology 7: 75–80, 1979
Bolvig Hansen L, Larsen N-E. Plasma concentrations of perfenazine and its sulphoxide metabolite during continuous oral treatment. Psychopharmacology 53: 127–130, 1977
Bolvig Hansen L, Larsen N-E. Plasma levels of perphenazine related to clinical effect and extrapyramidal side-effects. In Gram et al. (Eds) Clinical pharmacology in psychiatry — bridging the experimental-therapeutic gap, pp. 175–181, Macmillan, London, 1983
Bolvig Hansen L, Larsen N-E. Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice. Psychopharmacology 87: 16–19, 1985
Bolvig Hansen L, Larsen N-E, Gulmann N. Dose-response relationships of perphenazine in the treatment of acute psychoses. Psychopharmacology 78: 112–115, 1982
Brooks MA, Didonato G, Blumenthal HP. Determination of chlorprothixene and its sulfoxide metabolite in plasma by high-performance liquid chromatography with ultraviolet and amperometric detection. Journal of Chromatography 337: 351–362, 1985
Calil HM, Avery DH, Hollister LE, Creese I, Snyder SH. Serum levels of neuroleptics measured by dopamine radio receptor assay and some clinical observations. Psychiatry Research 1: 39–44, 1979
Casper R, Garver DL, Dekirmenjian H, Chang S, Davis JM. Phenothiazine levels in plasma and red blood cells. Their relationship to clinical improvement in schizophrenia. Archives of General Psychiatry 37: 301–305, 1980
Cohen BM, Lipinski JF, Harris PQ, Pope HG, Friedman M. Clinical use of the radioreceptor assay for neuroleptics. Psychiatry Research 1: 173–178, 1980a
Cohen BM, Lipinski JF, Pope HG, Harris PQ, Altesman RI. Neuroleptic blood levels and therapeutic effect. Psychopharmacology 70: 191–193, 1980b
Cohen BM, Baldessarini RJ. Haloperidol levels and clinical response. American Journal of Psychiatry 138: 1513–1514, 1981
Cooper TB. Plasma level monitoring of antipsychotic drugs. Clinical Pharmacokinetics 3: 14–38, 1978
Cooper JK, Mckay G, Midha KK. Subnanogram quantitation of chlorpromazine in plasma by high-performance liquid chromatography with electrochemical detection. Journal of Pharmaceutical Sciences 72: 1259–1262, 1983
Cooper TB, Kelly RG. GLC analysis of loxapine, amoxapine and their metabolites in serum and urine. Journal of Pharmaceutical Sciences 68: 216–219, 1979
Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481–483, 1976
Creese I, Snyder SH. A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood. Nature 270: 180–182, 1977
Csernansky JG, Kaplan J, Holman CA, Hollister LE. Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients. Psychopharmacology 81: 115–118, 1983
Curry SH. Antipsychotic agents. Chlorpromazine: pharmacokinetics, plasma levels, and clinical response. In Burrows & Norman (Eds) Psychotropic drugs. Plasma concentration and clinical response, pp. 243–286, Marcel Dekker, New York, 1981
Dahl SG. Pharmacokinetics of methotrimeprazine after single and multiple doses. Clinical Pharmacology and Therapeutics 19: 435–442, 1976
Dahl SG, Strandjord RE. Pharmacokinetics of chlorpromazine after single and chronic dosage. Clinical Pharmacology and Therapeutics 21: 437–448, 1977
Dahl SG, Strandjord RE, Sigfusson S. Pharmacokinetics and relative bioavailability of levomepromazine after repeated administration of tablets and syrup. European Journal of Clinical Pharmacology 11: 305–310, 1977
Dahl SG. Monitoring of phenothiazine plasma levels in psychiatric patients. In Saletu et al. (Eds) Neuro-Psychopharmacology, pp. 567–575, Pergamon Press, Oxford, 1979
Dahl SG. Pharmacokinetic aspects of new antipsychotic drugs. Neuropharmacology 20: 1299–1302, 1981
Dahl SG. Active metabolites of neuroleptic drugs: Possible contribution to therapeutic and toxic effects. Therapeutic Drug Monitoring 4: 33–40, 1982
Dahl SG, Bratlid T, Lingjaerde O. Plasma and erythrocyte levels of methotrimeprazine and two of its nonpolar metabolites in psychiatric patients. Therapeutic Drug Monitoring 4: 81–87, 1982a
Dahl SG, Johnsen H, Lee CR. Gas chromatographic mass spectrometric identification of O-demethylated and mono-hydroxylated metabolites of levomepromazine in blood from psychiatric patients by selected ion recording with high resolution. Biomedical Mass Spectrometry 9: 534–538, 1982b
Dahl SG, Hals P-A, Johnsen H, Morel E, Lloyd KG. Possible role of hydroxymetabolites in the action of neuroleptics. In Gram et al. (Eds) Clinical pharmacology in psychiatry — bridging the experimental-therapeutic gap, pp. 136–149, Macmillan, London, 1983
Davis JM, Bettis DB, Dekirmenjian H, Ericksen SE, Garver DL. Plasma levels of neuroleptics and antipsychotic response. In Klawans (Ed.) Clinical neuropharmacology, Vol. 3, pp. 85–102, Raven Press, New York, 1978
Davis JM, Ericksen SE, Hurt S, Chang SS, Javaid JI, et al. Haloperidol plasma levels and clinical response: basic concepts and clinical data. Psychopharmacology Bulletin 21: 48–51, 1985
Dhar AK, Kutt H. Improved liquid-chromatographic determination of haloperidol in plasma. Clinical Chemistry 30: 1228–1230, 1984
Dudley J, Rauw G, Hawes EM, Keegan DL, Midha KK. Correlation of fluphenazine plasma levels versus clinical response in patients: a pilot study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 7: 791–795, 1983
Dysken MW, Javaid JI, Chang SS, Schaffer C, Shahid A, et al. Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology 73: 205–210, 1981
Ereshefsky L, Davis CM, Harrington CA, Jann MW, Browning JL, et al. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients. Journal of Clinical Psychopharmacology 4: 138–142, 1984
Escobar JI, Barron A, Kiriakok R. Serum levels of fluphenazine: effect of dosage and route of administration and relation to side effects and clinical response. Psychopharmacology Bulletin 19: 131–134, 1982
Evans L. Butyrophenones. Plasma levels and therapeutic effect. In Burrows & Norman (Eds) Psychotropic drugs: plasma concentration and clinical response, pp. 319–330, Marcel Dekker, New York, 1981
Extein I, Augusthy KA, Gold MS, Pottash ALC, Martin D, et al. Plasma haloperidol levels and clinical response in acute schizophrenia. Psychopharmacology Bulletin 18(4): 156–158, 1982
Fairbairn AF, Rowell FJ, Hui SM, Hassanyeh F, Robinson AJ, et al. Serum concentration of depot neuroleptics in tardive dyskinesia. British Journal of Psychiatry 142: 579–583, 1983
Garver DL, Dekirmenjian H, Davis JM, Casper R, Ericksen S. Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazine. American Journal of Psychiatry 134: 304–307, 1977
Garver DL, Hirschowitz J, Glicksteen GA, Kanter DR, Mavroidis ML. Haloperidol plasma and red blood cell levels and clinical antipsychotic response. Journal of Clinical Psychopharmacology 4: 133–137, 1984
Gjerris A, Bech P, Broen-Christensen C, Geisler A, Klysner R, et al. Haloperidol plasma levels in relation to antimanic effect. In Usdin et al. (Eds) Clinical pharmacology in psychiatry — neuroleptic and antidepressant research, pp. 227–232, Macmillan, London, 1981
Gualtieri CT, Golden R, Evans RW, Hicks RE. Blood level measurement of psychoactive drugs in pediatric psychiatry. Therapeutic Drug Monitoring 6: 127–141, 1984
Gupta RN, Bartolucci G, Molnar G. Analysis of chlorpromazine in plasma: Effect of specimen storage. Clinica Chimica Acta 109: 351–354, 1981
Hayashi O, Miyoshi S, Higashimura T. Blood concentration and clinical effect of haloperidol therapy in combination with levomepromazine. Folia Psychiatrica et Neurologica Japonica 36: 459, 1982
Hays SE, Poland RE, Rubin RT. Prolactin releasing potencies of antipsychotic and related nonantipsychotic compounds in female rats: relation to clinical potencies. Journal of Pharmacology and Experimental Therapeutics 214: 362–367, 1980
Howes CA, Pullar T, Sourindhrin I, Mistra PC, Capel H, et al. Reduced steady-state plasma concentrations of chlorpromazine and indomethacin in patients receiving cimetidine. European Journal of Clinical Pharmacology 24: 99–102, 1983
Itoh H, Yagi G, Ohtsuka N, Iwamura K, Ichikawa K. Serum level of haloperidol and its clinical significance. Progress in Neuro Psychopharmacology and Biological Psychiatry 4: 171–183, 1980
Itoh H, Yagi G, Fujii Y, Iwamura K, Ichikawa K. The relationship between haloperidol blood levels and clinical responses. Progress in Neuro-Psychopharmacology and Biological Psychiatry 8: 285–292, 1984a
Itoh H, Yagi G, Tateyama M, Fujii Y, Iwamura K, et al. Monitoring of haloperidol serum levels and its clinical significance. Progress in Neuro-Psychopharmacology and Biological Psychiatry 8: 51–62, 1984b
Jann MW, Ereshefsky L, Saklad SR, Richards A, Davis CM. Haloperidol and reduced haloperidol plasma levels in schizophrenic patients. Drug Intelligence and Clinical Pharmacy 18: 507, 1984
Jatlow PI, Miller R, Swigar M. Measurement of haloperidol in human plasma using reversed-phase high performance liquid chromatography. Journal of Chromatography 237: 233–238, 1982
Johnsen H, Dahl SG. Identification of O-demethylated and ring-hydroxylated metabolites of methotrimeprazine (levomepromazine) in man. Drug Metabolism and Disposition 10: 63–67, 1982
Jeste DV, Linnoila M, Wagner R, Wyatt RJ. Serum neuroleptic concentrations and tardive dyskinesia. Psychopharmacology 76: 377–380, 1982
Jørgensen A. Metabolism and pharmacokinetics of antipsychotic drugs. In Bridges & Chasseaud (Eds) Progress in drug metabolism, Vol. 9, Taylor and Francis, London, in press, 1985
Kleinman JE, Bigelow LB, Rogol A, Weinberger DL, Nasrallah HA, et al. A clinical trial of 7-hydroxychlorpromazine in chronic schizophrenia. In Usdin et al. (Eds) Phenothiazines and structurally related drugs: basic and clinical studies, pp. 275–278, Elsevier North Holland, New York, 1980
Kogan MJ, Pierson D, Verebey K. Quantitative determination of haloperidol in human plasma by high-performance liquid chromatography. Therapeutic Drug Monitoring 5: 485–489, 1983
Korpi ER, Costakos D, Kleinman JE, Linnoila M, Wyatt RJ. Reduced haloperidol: a possible active metabolite of haloperidol. Federation Proceedings 42: 1152, 1983a
Korpi ER, Phelps BH, Granger H, Chang W-H, Linnoila M, et al. Simultaneous determination of haloperidol and its reduced metabolite in serum and plasma by isocratic liquid chromatography with electrochemical detection. Clinical Chemistry 29: 624–628, 1983b
Korpi ER, Wyatt RJ. Reduced haloperidol: effects on striatal dopamine metabolism and conversion to haloperidol in the rat. Psychopharmacology 83: 34–37, 1984
Kucharski LT, Alexander P, Tune L, Coyle J. Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients. Psychopharmacology 82: 194–198, 1984
Lader M. Monitoring plasma concentrations of neuroleptics. Pharmacopsychiatry 9: 170–177, 1976
Larsson M, Forsman A. A high-performance liquid chromatographic method for the assay of perphenazine and its dealkylated metabolite in serum after therapeutic doses. Therapeutic Drug Monitoring 5: 225–228, 1983
Larsson M, Forsman A, Ohman R. A high-performance liquid chromatographic method for the determination of haloperidol and reduced haloperidol in serum. Current Therapeutic Research 34: 999–1008, 1983
Larsson M, Axelsson R, Forsman A. On the pharmacokinetics of perphenazine: a clinical study of perphenazine enanthate and decanoate. Current Therapeutic Research 36: 1071–1088, 1984
Lewis MH, Mobilio JM, Rissmiller DJ, Mailman RB. Thioridazine pharmacodynamics: clinical effects may depend upon drug metabolism. Journal of the American Osteopathic Association 84 (Suppl.): 124–128, 1984
Lindenmayer JP, Smith D, Katz I. Radioreceptor assay of neuroleptics in refractory chronic schizophrenic patients. Journal of Clinical Psychiatry 45: 117–119, 1984
Linkowski P, Houbain P, VonFrenckell R, Mendlewicz J. Haloperidol plasma levels and clinical response in paranoid schizophrenics. European Archives of Psychiatry and Neurological Sciences 234: 231–236, 1984
Linnoila M, Dorrity F. Measurement of plasma and erythrocyte chlorpromazine and N-monodesmethylchlorpromazine levels by gas chromatography with a nitrogen sensitive detector. Acta Pharmacologica et Toxicologica 42: 264–270, 1978
Linnoila M, Viukari M, Vaisanen K, Auvinen J. Effect of anticonvulsants on plasma haloperidol and thioridazine levels. American Journal of Psychiatry 137: 819–821, 1980
Magliozzi JR, Hollister LE, Arnold KV, Earle GM. Relationship of serum haloperidol levels to clinical response in schizophrenic patients. Americ. J. Psych. 138: 365–367, 1981
Mailman RB, DeHaven DL, Halpern EA, Lewis MH. Serum effects confound the neuroleptic radioreceptor assay. Life Sciences 34: 1057–1064, 1984a
Mailman RB, Pierce JP, Crofton KM, Petitto J, DeHaven DL, et al. Thioridazine and the neuroleptic radioreceptor assay. Biological Psychiatry 19: 833–847, 1984b
Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL. Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology 81: 354–356, 1983
Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL. Therapeutic blood levels of fluphenazine: plasma or RBC determinations? Psychopharmacology Bulletin 20: 168–170, 1984a
Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL. Fluphenazine plasma levels and clinical response. Journal of Clinical Psychiatry 45: 370–373, 1984b
Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL. Clinical relevance of thiothixene plasma levels. Journal of Clinical Psychopharmacology 4: 155–157, 1984c
Mavroidis ML, Garver DL, Kanter DR, Hirschowitz J. Plasma haloperidol levels and clinical response: Confounding variables. Psychopharmacology Bulletin 21: 62–65, 1985
May PA, Van Putten T. Plasma levels of chlorpromazine in schizophrenia. A critical review of the literature. Archives of General Psychiatry 35: 1081–1087, 1978
May PRA, Van Putten T, Jenden DJ, Yale J, Dixon WJ. Chlorpromazine blood and saliva levels and the outcome of treatment in schizophrenic patients. Archives of General Psychiatry 38: 202–207, 1981
McBurney A, George S. High-performance liquid chromatography of haloperidol in serum at the concentrations achieved during chronic therapy. Journal of Chromatography 308: 387–392, 1984
McCreadie RG, Mackie M, Wiles DH, Jørgensen A, Hansen V, et al. Within-individual variation in steady state plasma levels of different neuroleptics and prolactin. British Journal of Psychiatry 144: 625–629, 1984
Meitzer HY, Busch DA, Fang VS. Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Research 9: 271–283, 1983
Mendlewicz J, Linkowski P, Alexandre J, Schoutens A. Haloperidol plasma levels and clinical response in schizophrenia. In Usdin et al. (Eds) Clinical pharmacology in psychiatry — neuroleptic and antidepressant research, pp. 233–237, Macmillan, London, 1981
Miller DD, Hershey LA, Duffy JP. Serum haloperidol concentrations and clinical response in acute psychosis. Drug Intelligence and Clinical Pharmacy 17: 445, 1983
Modestin J, Petrin A. Beziehung zwishen Plasma-konzentration und klinischer Wirkung von Neuroleptika und Antidepressiva. International Journal of Clinical Pharmacology 13: 11–21, 1976
Moulin MA, Davy JP, Debruyne D, Andersson JC, Bigot MC, et al. Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients. Psychopharmacology 76: 346–350, 1982
Morselli PL. Clinical significance of neuroleptic plasma level monitoring. In Usdin et al. (Eds) Clinical pharmacology in psychiatry — neuroleptic and antidepressant research, pp. 199–209, Macmillan, London, 1981
Morselli PLM, Bianchetti G, Dugas M. Haloperidol plasma level monitoring in neuropsychiatric patients. Therapeutic Drug Monitoring 4: 51–58, 1982
Morselli PLM, Bianchetti G, Dugas M. Therapeutic drug monitoring of psychotropic drugs in children. Pediatric Pharmacology 3: 149–156, 1983
Neborsky RJ, Janowsky DS, Perel JM. Red blood cell/plasma haloperidol ratios and antipsychotic efficacy. Psychiatry Research 6: 123–124, 1982
Neborsky RJ, Janowsky DS, Perel JM, Munson E, Depry D. Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms. Journal of Clininal Psychiatry 45: 10–13, 1984
Newman DC, Epperly M, Sangarasivam S, Maruta T, Homburger HA. Neuroleptic levels in serum: Clinical usefulness in schizophrenic patients. Clinical Research 32: 741A, 1984
Norman TR, Burrows G. Methods for the measurement of psychotropic drugs. Antipsychotics and antianxiety agents. In Burrows & Norman (Eds) Psychotic drugs: plasma concentration and clinical response, pp. 83–138, Marcel Dekker, New York, 1981
Nyberg G, Axelsson R, Mårtensson E. Cerebrospinal fluid concentrations of thioridazine and its main metabolites in psychiatric patients. European Journal of Clinical Pharmacology 19: 139–148, 1981
Poey J, Puig P, Bourbon C, Bourbon P. Dosage de la fluphenazine dans le serum humain par chromatographie en phase liquide. Analysis 13: 65–68, 1985
Potkin SG, Shen Y, Zhou D, Pardes H, Shu L, et al. Does a therapeutic window for plasma haloperidol exist?: Preliminary Chinese data. Psychopharmacology Bulletin 21: 59–61, 1985
Reifler BV, Ward N, Davis CM, Freidel RO. Thiothixene plasma levels and clinical response in acute schizophrenia. Journal of Clinical Psychiatry 42: 207–211, 1981
Rivera-Calimlim L. Problems in therapeutic blood monitoring of chlorpromazine. Therapeutic Drug Monitoring 4: 41–49, 1982
Rivera-Calimlim L, Kerzner B, Karch FE. Effect of lithium on plasma chlorpromazine levels. Clinical Pharmacology and Therapeutics 23: 451–455, 1978
Rivera-Calimlim L, Hershey L. Neuroleptic concentrations and clinical response. Annual Review of Pharmacology and Toxicology 24: 361–386, 1984
Rivera-Calimlim R, Castaneda L, Lasagna L. Effects of mode of management on plasma chlorpromazine in psychiatric patients. Clinical Pharmacology and Therapeutics 14: 978–986, 1973
Rowell FJ, Rich CG, Hall G, Fairbairn AF, Hassanyeh F. Serum chlorpromazine levels in tardive dyskinesia. British Journal of Clinical Pharmacology 15: 141p–142p, 1983
Rubin R, Forsman A, Heykants J, Ohman R, Tower B, et al. Serum haloperidol determinations in psychiatric patients. Archives of General Psychiatry 37: 1069–1074, 1980
Rubin R, Poland RE. Serum haloperidol determinations and their contribution to the treatment of schizophrenia. In Gram et al. (Eds) Clinical Pharmacology in Psychiatry — bridging the experimental-therapeutic gap, pp. 217–225, Macmillan, London, 1983
Sajadi C, Smith RC, Shvartsburd A, Morton V, Mirabi M, et al. Neuroleptic blood levels in outpatient maintenance therapy of schizophrenia. Psychopharmacology Bulletin 20: 110–113, 1984
Sakalis G, Traficante L. Antipsychotic agents. Fluphenazine. In Burrows & Norman (Eds) Psychotropic drugs: plasma concentration and clinical response, pp. 287–302, Marcel Dekker, New York, 1981
Shvartsburd A, Dekirmejian H, Smith R. Blood levels of haloperidol in schizophrenic patients. Journal of Clinical Psychopharmacology 3: 7–12, 1983
Shvartsburd A, Nwokeafor V, Smith RC. Red blood cell and plasma levels of thioridazine and mesoridazine in schizophrenic patients. Psychopharmacology 82: 55–61, 1984a
Shvartsburd A, Sajadi C, Morton V, Mirabi M, Gordon J, et al. Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients. Journal of Clinical Psychopharmacology 4: 194–198, 1984b
Silverstone T, Cookson J, Ball R, Chin CN, Jacobs D, et al. The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol. Journal of Psychiatric Research 18: 255–268, 1984
Simpson GM, Cooper TB, Bark N, Sud I, Lee JH. Effect of antiparkinsonian medication on plasma levels of chlorpromazine. Archives of General Psychiatry 37: 205–208, 1980
Smith RC, Vroulis G, Misra CH, Schoolar J, DeJohn C, et al. Receptor techniques in the study of plasma levels of neuroleptics and antidepressant drugs. Communications in Psychopharmacology 4: 451–465, 1980
Smith RC, Vroulis G, Shvartsburd A, Allen R, Lewis N, et al. RBC and plasma haloperidol and clinical response in schizophrenia. American Journal of Psychiatry 139: 1054–1056, 1982
Smith RC, Baumgartner R, Misra CH, Mauldin M, Shvartsburd A, et al. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays. Archives of General Psychiatry 41: 1044–1049, 1984a
Smith RC, Baumgartner R, Ravichandran GK, Shvartsburd A, Schoolar JC, et al. Plasma and red cell levels of thioridazine and clinical response in schizophrenia. Psychiatry Research 12: 287–296, 1984b
Smith RC, Baumgartner R, Burd A, Ravichandran GK, Mauldin M. Haloperidol and thioridazine drug levels and clinical response in schizophrenia: comparison of gas-liquid chromatography and radioreceptor drug level assays. Psychopharmacology Bulletin 21: 52–58, 1985
Stoll AL, Baldessarini RJ, Cohen BM, Finklestein SP. Assay of plasma thioridazine and metabolites by high-performance liquid chromatography with amperometric detection. Journal of Chromatography 307: 457–463, 1984
Swigar ME, Jatlow PI, Goicoechea N, Opsahl C, Bowers MB. Ratio of serum prolactin to haloperidol and early clinical outcome in acute psychosis. American Journal of Psychiatry 14: 1281–1283, 1984
Tang SW, Glaister J, Davidson L, Toth R, Jeffries JJ, et al. Total and free plasma neuroleptic levels in schizophrenic patients. Psychiatry Research 13: 285–293, 1984
Tune LE, Creese I, DePaulo JR, Slavney PR, Coyle JT, et al. Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia. American Journal of Psychiatry 137: 187–190, 1980
Tune L, Coyle JT. Acute extrapyramidal effects: serum levels of neuroleptics and anticholinergics. Psychopharmacology 75: 9–15, 1981
Tune LE, Creese I, DePaulo JR, Slavney PR, Snyder SH. Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizophrenia. Journal of Nervous and Mental Disease 169: 60–63, 1981
Veste DV, Rosenblatt JE, Wagner RL, Wyatt RJ. High serum neuroleptic levels in tardive dyskinesia? New England Journal of Medicine 301: 1184, 1979
Van Putten T, May PRA, Jenden DJ. Does a plasma level of chlorpromazine help? Psychological Medicine 11: 729–734, 1981
Van Putten T, May PRA, Marder SR, Wilkins JN, Rosenberg BJ. Plasma levels of thiothixene by radioreceptor assay: clinical usefulness. Psychopharmacology 79: 40–44, 1983
Van Putten T, Marder SR, May PRA, Poland RE, O’Brien RP. Plasma levels of haloperidol and clinical response. Psychopharmacology Bulletin 21: 69–72, 1985
Weissman N, Weinstein D, Babich-Armstrong M. Loxapine/amoxapine and their 7-hydroxylated and 8-hydroxylated metabolites in serum by HPLC. Clinical Chemistry 29: 1158, 1983
Wells CE, Juenge EC, Furman WB. Simultaneous assay of thioridazine and its major metabolites in plasma at single dosage levels with a novel report of 2 ring sulfoxides of thioridazine. Journal of Pharmaceutical Sciences 72: 622–625, 1983
Wiles DH, Franklin M, Dencker SJ, Johansson R, Lundin U, et al. Plasma fluphenazine and prolactin levels in schizophrenic patients during treatment with low and high doses of fluphenazine enanthate. Psychopharmacology 71: 131–136, 1980
Wistedt B, Jørgensen A, Wiles D. A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency. Psychopharmacology 78: 301–304, 1982
Wistedt B, Johanidesz G, Omerhodzic M, Arthur H, Bertilsson L, et al. Plasma haloperidol levels and clinical response in acute schizophrenia. Nordisk Psykiatrisk Tidsskrift 38: 9–13, 1984
Wode-Helgodt B, Borg S, Fyrö B, Sedvall G. Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatrica Scandinavica 58: 149–173, 1978
Wode-Helgodt B, Alfredsson G. Concentrations of chlorpromazine and two of its active metabolites in plasma and cerebrospinal fluid of psychotic patients treated with fixed drug doses. Psychopharmacology 73: 55–62, 1981
Yesavage JA, Becker J, Werner PD, Mills MJ, Holman CA, et al. Serum level monitoring of thiothixene in schizophrenia: acute single-dose levels at fixed doses. American Journal of Psychiatry 139: 174–178, 1982
Yesavage JA, Holman CA, Cohn R, Lombrozo L. Correlation of initial thiothixene serum levels and clinical response. Comparison of fluorometric, gas chromatographic, and RBC assays. Archives of General Psychiatry 40: 301–304, 1983
Young RC, Nysewander RW. Intrapatient variability of serial plasma chlorpromazine concentrations. Research Communications in Psychology Psychiatry and Behavior 9: 345–348, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dahl, S.G. Plasma Level Monitoring of Antipsychotic Drugs Clinical Utility. Clin-Pharmacokinet 11, 36–61 (1986). https://doi.org/10.2165/00003088-198611010-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-198611010-00003